RecruitingPhase 2NCT07241546

Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

A Randomized, Double-blind, Placebo-controlled Phase 2a Study of ARO-RAGE Inhalation Solution to Assess Efficacy on Small Airway Dysfunction in Allergen-induced Mild Asthma

Sponsor

Arrowhead Pharmaceuticals

Enrollment

36 participants

Start Date

Mar 30, 2026

Study Type

INTERVENTIONAL

Conditions

Asthma

Summary

The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria4

Clinically stable, mild atopic asthma (FEV1 ≥70% predicted)
Established allergy confirmed by positive skin prick test at screening
Willing and able to perform lung function tests and other study-related procedures
Participants of childbearing potential must consent to use a method of highly-effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last investigational product administration, whichever is later

Exclusion Criteria3

Concomitant diagnosis of a clinically important pulmonary disease other than asthma
Use of corticosteroids, immunosuppressives, or anti-inflammatory medications that interfere with inhaled challenges or inflammation, or chronic use of any other medication for treatment of allergic asthma
History or current medical condition contraindicating methacholine challenge

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGARO-RAGE

Inhalation of nebulized solution

DRUGPlacebo

Calculated volume to match active treatment by inhalation of nebulized solution

Locations(2)

Research Site 1

Vancouver, British Columbia, Canada

Research Site 2

Calgary, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07241546

Related Trials

Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis

NCT0724557612 locations

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319230 locations